EyeGene Inc.

A185490

KR7185490000

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
3,110 ^KRW	-.--%		-4.01%	-27.08%

2023	EyeGene Inc. announced that it has received KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI
2023	EyeGene Inc. announced that it expects to receive KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI

EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index

April 07, 2022 at 12:00 am EDT

Latest news about EyeGene Inc.

EyeGene Inc. announced that it has received KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	Dec. 20	CI
EyeGene Inc. announced that it expects to receive KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	Dec. 12	CI
EyeGene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
EyeGene Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	22-04-07	CI
Maravai LifeSciences : Says Unit TriLink To Supply Proprietary Technology to EyeGene for Production of COVID-19 Vaccine	21-10-04	MT
EyeGene Inc.(KOSDAQ:A185490) added to S&P Global BMI Index	21-09-20	CI
EyeGene Inc. announced that it has received KRW 22 billion in funding from a group of investors	20-09-17	CI
EyeGene Inc. announced that it expects to receive KRW 22 billion in funding from a group of investors	20-09-15	CI
EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	19-09-23	CI
EyeGene Inc. announced that it has received KRW 29.9998664 billion in funding from Meritz Securities Co., Ltd., Investment Arm, IBK Capital Corporation, Korea Investment & Securities Co., Ltd., Investment Arm	18-09-27	CI
EyeGene Inc. announced that it expects to receive KRW 29.9998664 billion in funding from a group of investors	18-09-19	CI
EyeGene Inc. announced that it has received KRW 5.4 billion in funding from DSC Investment Inc., G.N.TECH Venture Capital Co., Ltd., Korea Investment Partners Co. Ltd.	17-12-14	CI
EyeGene Inc. announced that it has received KRW 12.6 billion in funding from Korea Investment Partners Co. Ltd., G.N.TECH Venture Capital Co., Ltd., DSC Investment Inc.	17-12-13	CI
EyeGene Inc. announced that it expects to receive funding from Korea Investment Partners Co. Ltd., G.N.TECH Venture Capital Co., Ltd., DSC Investment Inc. and other investors	17-12-11	CI
EyeGene Inc. announced that it expects to receive KRW 5.4 billion in funding from DSC Investment Inc., G.N.TECH Venture Capital Co., Ltd., Korea Investment Partners Co. Ltd.	17-12-11	CI
EyeGene, Inc.(XKON:A185490) added to S&P Global BMI Index	16-03-21	CI
EyeGene, Inc. completed the sale of ICM co., Ltd.	15-12-29	CI
EyeGene, Inc. agreed to sell ICM co., Ltd for KRW 90 million.	15-12-28	CI
LB Investment Inc. through its fund LB Gemini New Growth Fund 16 acquired an unknown stake in EyeGene, Inc. from KoFC-Hanwha Pioneer Champ 2010 Fund 14 and 09-4 Hanwha Venture Investment Partnership, funds of Hanwha Investment Corp for KRW 1.7 billion.	14-11-03	CI

EyeGene, Inc. is a Korea-based company mainly engaged in the development of therapeutics, diagnostics, and technologies for eye-related diseases. The Companyâs products consist of EG-Mirotin, which is a therapeutics of ocular angiogenesis of the diagnostic of early-stage of diabetic retinopathy (DR) and retinopathy of prematurity (ROP); EG-Decorin, a topical ointment for pressure ulcer and diabetic foot ulcer; EG-HPV, a human papillomavirus vaccine; EGS, a scarless wound repair agent, and EG-Vac, a novel vaccine adjuvant for various vaccine preparations.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EYEGENE INC.	-27.08%	60.74M
ELI LILLY AND COMPANY	+33.45%	704B
NOVO NORDISK A/S	+28.59%	577B
JOHNSON & JOHNSON	-3.89%	348B
MERCK & CO., INC.	+18.64%	327B
ABBVIE INC.	+5.03%	288B
ASTRAZENECA PLC	+14.70%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-3.93%	147B